Patents by Inventor Ferenc Makra

Ferenc Makra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS
    Publication number: 20200222352
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Application
    Filed: November 15, 2019
    Publication date: July 16, 2020
    Inventor: Ferenc Makra
  • FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS
    Publication number: 20180133189
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Application
    Filed: May 30, 2017
    Publication date: May 17, 2018
    Inventor: Ferenc Makra
  • FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS
    Publication number: 20160038451
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Application
    Filed: October 20, 2015
    Publication date: February 11, 2016
    Inventor: Ferenc Makra
  • FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS
    Publication number: 20140343107
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 20, 2014
    Applicant: QuRetino Therapeutics, Inc.
    Inventor: Ferenc Makra
  • Formulations and uses of retinoic acid receptor selective agonists
    Patent number: 8772273
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: July 8, 2014
    Assignee: QuRetino Therapeutics, Inc.
    Inventor: Ferenc Makra
  • Inhibitors of JNK
    Patent number: 8536172
    Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein p, q, Y?, r, R1, R2, X, X1, X2, X3, and X4 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: September 17, 2013
    Assignee: Roche Palo Alto LLC
    Inventors: Leyi Gong, Xiaochun Han, Ferenc Makra, Wylie Solang Palmer, Lubica Raptova
  • FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS
    Publication number: 20130085166
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Application
    Filed: October 4, 2011
    Publication date: April 4, 2013
    Inventor: Ferenc Makra
  • Inhibitors of JNK
    Publication number: 20110034470
    Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein p, q, Y?, r, R1, R2, X, X1, X2, X3, and X4 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
    Type: Application
    Filed: August 9, 2010
    Publication date: February 10, 2011
    Inventors: Leyi Gong, Xiaochun Han, Ferenc Makra, Wylie Solang Palmer, Lubica Raptova
  • Heterocyclic antiviral compounds
    Publication number: 20090093501
    Abstract: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3, R4 and Y are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPR.
    Type: Application
    Filed: September 18, 2008
    Publication date: April 9, 2009
    Inventors: Stephen Deems Gabriel, Xiao-Fa Lin, Ferenc Makra, David Mark Rotstein, Hanbiao Yang